Tilman Schneider-Hohendorf

Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis.

Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis.

Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.

Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels.

Immunological and clinical consequences of treating a patient with natalizumab.

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Specific loss of cellular L-selectin on CD4+ T cells is associated with PML development during HIV infection.

Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity.

VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Trafficking of lymphocytes into the CNS.

Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid.

PML risk stratification using anti-JCV antibody index and L-selectin.

CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values.

CD8(+) T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing.

Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification.